Roche pushed its KRAS G12C program forward with new Phase 3 results that beat existing therapies in previously treated non-small cell lung cancer. The divarasib study, Krascendo-1, reported improvements in both overall survival and progression-free survival versus Amgen’s Lumakra and Bristol Myers Squibb’s Krazati for KRAS G12C patients after prior therapy. Roche did not disclose detailed efficacy or safety tables ahead of planned medical meeting presentations. The company said no new safety signals of concern emerged and that most treatment-related side effects were manageable and reversible. The headline implication is direct competitive pressure in an already established KRAS G12C setting, with Roche also testing a potentially larger market opportunity in earlier-line disease via Krascendo-2—divarasib plus Merck’s Keytruda versus Keytruda plus chemotherapy.